New hope for patients Who've run out of options: early trial tests novel blood cancer drug
NCT ID NCT07347171
Summary
This is a first-in-human study to test a new drug called CG009301 in adults with blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the body processes the drug. About 45 participants will receive the treatment to see if it shows any early signs of helping control their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Haematology Hospital of the Chinese Academy of Medical Sciences
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.